SMO and skin basal cell carcinoma: At this point in time, the US Food and Drug Administration (FDA) has already approved two inhibitors of SMO for the treatment of advanced BCC: Vismodegib (GDC-0449; 30 January 2012) and Sonidegib (LDE-225; 24 July 2015).